We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Get To Know Me
I am a medical oncologist and a laboratory scientist. As a member of the Genitourinary Oncology Service, I specialize in treating cancers of the prostate, bladder, kidney, testis, and other related cancers.
I treat my patients with chemotherapy, targeted therapies, immunotherapy, or combinations of these drugs. At Memorial Sloan Kettering Cancer Center (MSK), I work with other cancer experts, including surgeons and radiation oncologists, to develop an individual treatment plan for each patient.
Read more
I am very involved in clinical trials, particularly those of targeted drugs known as kinase inhibitors, which block pathways inside cancer cells that cause the cells to grow or spread. One area of focus in my research is studying patients who are known as extraordinary responders. These are people with difficult-to-treat cancers who are found to respond exceptionally well to a new drug, even though that drug does not work in most people with the same disease.
My laboratory in the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering completed the first whole-genome analysis of a patient with bladder cancer. This patient had a complete and durable response to a novel targeted drug that was effective in only a small minority of patients. By performing this analysis, we were able to determine what was genetically unique about this patient’s tumor. We are now testing the same drug in other patients whose tumors have a similar genetic profile.
As the Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO) at MSK, I also lead a multidisciplinary team of clinicians, geneticists, bioinformaticians, and laboratory scientists. The mission of the CMO is to integrate molecular and clinical information to develop therapies that are individualized to each patient’s cancer.
My colleagues and I work to make sure that all patients who come to MSK receive the best care possible, whether that means conventional or experimental therapies.
My Role at MSK
A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) medical oncologist is a cancer doctor who specializes in genitourinary (GU) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
Areas of Expertise
My Specialties
Genitourinary Oncology
Prostate Cancer
Education & Honors
Education
MD, University of Pennsylvania School of Medicine
Residencies
Internal Medicine - Barnes Jewish Hospital
Fellowships
Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center
Medicine - Weill Cornell Medical College
Board Certifications
Internal Medicine
Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
Aetna
In Network Coverage Type HMO, EPO PPO, POS, Transplant
Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Solit’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
We strive to keep reviews trustworthy, honest and fair.
Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David B. Solit discloses the following relationships and financial interests:
American Association for Cancer Research Professional Services and Activities
BridgeBio Inc. Professional Services and Activities
Elsie Biotechnologies, Inc. Equity; Professional Services and Activities
Fog Pharmaceuticals, Inc. Professional Services and Activities
Fore Biotherapeutics Equity; Professional Services and Activities
Function Oncology, Inc. Equity; Professional Services and Activities
Paige.AI, Inc. Professional Services and Activities
Pfizer, Inc. Professional Services and Activities
Pyramid Biosciences, Inc. Equity; Professional Services and Activities
Rain Therapeutics Inc. Professional Services and Activities
Scorpion Therapeutics, Inc. Equity; Professional Services and Activities
Vividion Therapeutics Equity
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
